Last updated: November 6, 2026
Diclegis is a prescription delayed-release combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg for nausea and vomiting of pregnancy in women who do not respond adequately to conservative management. Duchesnay commercializes the product in the United States. The market is structurally attractive because the indication is large, treatment often extends across multiple weeks, and the product has strong obstetric familiarity. Its financial trajectory is constrained by generic entry, limited differentiation from lower-cost alternatives, and the absence of publicly reported product-level revenue from private manufacturer Duchesnay [1].
What is Diclegis and how does it compete in nausea and vomiting of pregnancy?
Diclegis is an enteric or delayed-release prescription tablet taken on a scheduled basis rather than solely when symptoms occur. Each tablet contains 10 mg of doxylamine succinate and 10 mg of pyridoxine hydrochloride. The labeled maximum is four tablets daily, with dosing adjusted according to symptom severity [1].
The product competes in a treatment sequence that includes:
- Dietary and behavioral measures.
- Pyridoxine alone.
- Immediate-release doxylamine plus pyridoxine.
- Diclegis or equivalent delayed-release therapy.
- Other prescription antiemetics, including ondansetron, metoclopramide and promethazine.
- Intravenous therapy or hospitalization for hyperemesis gravidarum.
Diclegis has a commercial advantage in the first-line prescription segment because its active ingredients are familiar to obstetricians and its FDA indication directly covers nausea and vomiting of pregnancy. Its commercial limitation is that both ingredients have long histories of use outside the branded product, including over-the-counter doxylamine and vitamin B6.
How large is the addressable market?
Nausea and vomiting affect approximately 70% to 80% of pregnancies, while a smaller proportion develop symptoms requiring prescription treatment or clinical intervention [2]. The U.S. market is therefore broad, but the branded opportunity depends on:
- The number of pregnancies treated with prescription therapy.
- The share of patients receiving a branded delayed-release product.
- The average number of tablets used daily.
- Duration of treatment.
- Reimbursement and substitution behavior.
Treatment demand is recurring at the population level but not chronic at the patient level. The market resets with each pregnancy and is highly sensitive to birth rates.
When was Diclegis approved and what exclusivity did it receive?
The FDA approved Diclegis on April 8, 2013, under NDA 021876 [3]. The product was a reformulation and U.S. relaunch of a doxylamine-pyridoxine treatment lineage associated with Diclectin in Canada.
| Milestone |
Date |
Commercial significance |
| FDA approval of Diclegis |
April 8, 2013 |
Established U.S. prescription approval |
| U.S. commercial launch |
2013 |
Created a branded delayed-release pregnancy-nausea franchise |
| FDA approval of Bonjesta |
2016 |
Added a higher-strength, twice-daily formulation |
| Generic competition |
2023 onward |
Changed the market from branded exclusivity to multi-source supply |
Diclegis received FDA orphan-drug designation before approval, according to FDA product records. Orphan designation does not necessarily create a seven-year market-exclusivity period when the approved indication does not qualify as a rare disease indication at the relevant commercial scale. The principal commercial protection came from formulation patents, regulatory exclusivity, brand recognition and distribution rather than from a durable statutory monopoly.
What patents protect Diclegis and when does Diclegis lose exclusivity?
Diclegis protection has centered on the delayed-release combination formulation and related intellectual property rather than on new chemical entities. Doxylamine and pyridoxine are established active ingredients, which limits the ability to rely on composition-of-matter exclusivity.
The practical patent risk profile is as follows:
| Protection category |
Strategic value |
Current risk |
| Active ingredients |
Low |
Both ingredients are old and widely available |
| Delayed-release combination |
Moderate |
Can support formulation claims, but design-around risk exists |
| Dosing regimen |
Moderate to low |
Method-of-use claims may face validity and infringement challenges |
| Manufacturing process |
Moderate |
Can delay exact replication but rarely blocks all alternatives |
| Brand and physician familiarity |
Commercial rather than legal |
Erodes after generic entry |
The relevant U.S. patent estate should be assessed through the current FDA Orange Book and the corresponding patent records. Orange Book listings can include formulation and method-of-use patents, but listed patents do not establish validity or guarantee market exclusion. Generic applicants can challenge listed patents through Paragraph IV certifications or wait for listed patent terms to expire [4].
A key distinction is that Diclegis does not have the protection profile of a biologic, complex injectable or novel small molecule. A generic applicant can use the same active ingredients while pursuing a different formulation design, manufacturing route or labeling strategy.
What is the Orange Book status of Diclegis?
Diclegis is an NDA product listed in the FDA Orange Book. The Orange Book is the central source for approved therapeutic equivalents, patent listings and regulatory exclusivity information for small-molecule products [4].
The commercial implications are:
- An ANDA applicant can seek an AB-rated equivalent if it demonstrates pharmaceutical equivalence and bioequivalence.
- A Paragraph IV certification can trigger patent litigation.
- A successful generic applicant can enter after applicable patent and exclusivity barriers are resolved.
- Patent listings can affect the timing of approval but do not eliminate the risk of later generic competition.
The FDA label and Orange Book data should be read together. The label establishes the approved dosage form, active ingredients, warnings and administration schedule. The Orange Book establishes the listed patent and therapeutic-equivalence framework.
Which companies are challenging Diclegis and what generic entry risks exist?
Generic entry is the central threat to Diclegis revenue. The market has moved from a branded-only model to a generic-available model, with FDA-approved generic doxylamine succinate and pyridoxine hydrochloride delayed-release tablets entering the U.S. supply chain from 2023 onward.
The principal competitive groups are:
- Generic pharmaceutical companies with ANDAs for the same strength and dosage form.
- Manufacturers of immediate-release doxylamine and pyridoxine combinations.
- Compounded products and pharmacy-prepared alternatives.
- Branded Bonjesta, which is also controlled by Duchesnay.
- Other prescription antiemetics used off label or under different indications.
The most important generic launch scenarios are:
Scenario 1: Gradual generic substitution
Pharmacies substitute generic delayed-release tablets where payer rules permit. Diclegis retains a portion of demand through prescriber preference, patient familiarity and manufacturer support programs. Net price declines, but branded volume remains material.
Scenario 2: Rapid formulary conversion
Commercial insurers and pharmacy benefit managers place generic products on preferred tiers. Diclegis experiences sharp prescription and net-price erosion. Duchesnay protects revenue through contracting, adherence services and product differentiation.
Scenario 3: Partial substitution
Generic suppliers face manufacturing or distribution constraints, while some physicians continue prescribing Diclegis. The brand maintains a smaller premium segment, particularly among patients who have previously responded to the product.
The pregnancy market may exhibit slower substitution than routine chronic-care categories because physicians and patients are sensitive to safety, tolerability and consistency. That advantage is commercial, not a permanent legal barrier.
How strong is the Diclegis patent estate?
The estate is moderate in commercial value but weak relative to a novel-drug patent estate.
Strengths
- FDA-approved delayed-release dosage form.
- Specific prescription indication for nausea and vomiting of pregnancy.
- Established clinical-trial and safety record.
- Physician recognition in obstetrics.
- A formulation that is more difficult to replicate than a simple immediate-release tablet.
Weaknesses
- Old active ingredients.
- Limited chemical novelty.
- Potential design-around options.
- Generic pathway through ANDA approval.
- Method-of-use claims may face challenges involving obviousness, written description and infringement.
- Formulation patents may not prevent alternative delayed-release systems.
The estate is better positioned to delay exact copies than to prevent all competitive therapy. Its value depends on the scope and enforceability of listed claims, not merely on the existence of Orange Book entries.
What formulations are protected by Diclegis and Bonjesta?
Diclegis contains 10 mg/10 mg delayed-release tablets. Bonjesta contains 20 mg/20 mg extended-release tablets and is designed for twice-daily administration [5].
| Product |
Active ingredients per tablet |
Release profile |
Typical dosing concept |
| Diclegis |
10 mg doxylamine / 10 mg pyridoxine |
Delayed release |
Up to four tablets daily |
| Bonjesta |
20 mg doxylamine / 20 mg pyridoxine |
Extended release |
Twice-daily administration |
Bonjesta extends the franchise by offering a different strength and dosing schedule. It does not eliminate generic risk. A generic version of Diclegis can pressure the lower-strength product, while Bonjesta can retain value if physicians prefer its twice-daily regimen or if its specific formulation remains less exposed to substitution.
What is the FDA regulatory status of Diclegis?
Diclegis remains an FDA-approved prescription drug for nausea and vomiting of pregnancy. Its label includes a boxed warning regarding somnolence and cautions against use with alcohol or other central nervous system depressants [1].
The regulatory profile is comparatively stable:
- It is a conventional small-molecule product.
- It does not require biologics-licensing or biosimilar review.
- Generic applicants use the ANDA pathway.
- The main regulatory issues are bioequivalence, dosage-form performance, labeling and manufacturing quality.
- Post-approval safety monitoring remains relevant because the product is used during pregnancy.
Biosimilar risk is not applicable to Diclegis. The relevant competitive mechanism is generic substitution, not biosimilar interchangeability.
What patent litigation and settlement agreements affect Diclegis?
Diclegis litigation risk centers on ANDA patent challenges, formulation claims and the timing of generic approval. A Paragraph IV notice can result in a 30-month stay of final ANDA approval if the NDA holder files a timely infringement action under the Hatch-Waxman framework [6].
Publicly available commercial information does not establish a single settlement structure that governs the entire market. The key diligence points are:
- Whether a generic applicant made a Paragraph IV certification.
- Whether Duchesnay filed an infringement action within the statutory period.
- Whether the case ended in dismissal, settlement, judgment or license.
- Whether the agreement included an authorized-generic provision.
- Whether the settlement date permitted launch before or after patent expiry.
An authorized generic or licensed generic can preserve some manufacturer economics while accelerating price erosion. A later court ruling invalidating or narrowing formulation claims can accelerate entry across multiple applicants.
How has Diclegis revenue changed over time?
Duchesnay is privately held and does not publish a public-company segment report that isolates Diclegis revenue, unit volume, gross margin or cash flow. Product-level revenue estimates from prescription databases and market research may differ materially because they use different channels and list-to-net assumptions.
The financial trajectory is nevertheless clear:
| Period |
Financial position |
| 2013-2015 |
Launch investment, physician education and market formation |
| 2016-2019 |
Franchise expansion through Bonjesta and broader prescribing |
| 2020-2022 |
Mature branded revenue with continued dependence on reimbursement and patient support |
| 2023 onward |
Generic-entry pressure, lower net pricing and greater need for brand retention |
Gross-to-net pressure is likely to increase after generic entry because branded discounts, rebates, copay assistance and payer concessions rise while the list price becomes less relevant to realized revenue. Product profitability can remain attractive if manufacturing costs are low, but absolute revenue is likely to decline as generic share increases.
The biggest financial drivers are:
- Generic substitution rate.
- Brand-to-generic price differential.
- U.S. birth volume.
- Insurance coverage and prior authorization.
- Bonjesta conversion.
- Promotional spending.
- Manufacturing and distribution reliability.
- Patient-support program effectiveness.
How does Diclegis compare with Bonjesta and generic doxylamine-pyridoxine?
| Attribute |
Diclegis |
Bonjesta |
Generic delayed-release product |
| Strength |
10 mg/10 mg |
20 mg/20 mg |
Generally equivalent to reference strength |
| Dosing |
Up to four tablets daily |
Twice daily |
Product-specific labeling |
| Brand owner |
Duchesnay |
Duchesnay |
Multiple ANDA applicants |
| FDA pathway |
NDA |
NDA |
ANDA |
| Price position |
Premium brand |
Premium brand |
Lower-cost |
| Substitution |
Direct generic risk |
Less direct, but franchise risk remains |
Gains payer preference |
| Differentiation |
Established pregnancy indication and delayed release |
Higher strength and simplified dosing |
Price and availability |
Diclegis remains the more exposed product because its direct generic equivalents target the same strength and dosage form. Bonjesta can absorb some brand demand but is also vulnerable to therapeutic substitution.
What is the outlook for Diclegis’ commercial franchise?
The franchise is likely to remain commercially viable but structurally smaller after generic penetration. Diclegis has durable clinical recognition and an approved indication that supports continued prescribing. Its economic ceiling is limited by the old active ingredients, generic availability and the absence of publicly verifiable product-level financial disclosure.
The most probable outcome is a branded niche with declining net sales, supported by:
- Obstetrician familiarity.
- Patient response and tolerability.
- Brand access programs.
- Supply reliability.
- Bonjesta conversion.
- Differentiated commercial contracting.
A rapid loss of preferred formulary status would create the sharpest downside. A slower generic rollout, limited supplier capacity or continued physician preference would extend the brand’s revenue tail.
Key Takeaways
- Diclegis is a prescription delayed-release doxylamine-pyridoxine product approved by the FDA in 2013.
- Its commercial protection is based on formulation, labeling, regulatory history and brand recognition, not new-chemical-entity exclusivity.
- Generic delayed-release products began changing the U.S. market from 2023 onward.
- The product is subject to generic risk, not biosimilar risk.
- Bonjesta provides franchise support through a higher-strength, twice-daily formulation.
- Duchesnay’s private ownership limits public visibility into product revenue, margins and cash flow.
- The likely financial trajectory is mature branded revenue followed by lower net pricing, declining share and a residual premium segment.
- The patent estate may delay exact copies but is unlikely to block all formulation workarounds indefinitely.
Frequently Asked Questions
Is Diclegis still protected by patents?
Diclegis may remain covered by listed formulation or method-of-use patents, but patent listings do not guarantee enforceability or prevent alternative generic formulations.
Is there a generic version of Diclegis?
Yes. FDA-approved generic delayed-release doxylamine succinate and pyridoxine hydrochloride products have entered the U.S. market, creating direct substitution risk.
Is Diclegis the same as over-the-counter Unisom and vitamin B6?
The active ingredients are related, but Diclegis is an FDA-approved prescription product with a specific delayed-release formulation, manufacturing controls and pregnancy-related indication.
Can a generic company launch Diclegis before all patents expire?
It can potentially launch after a successful Paragraph IV challenge, an agreement with the patent holder, a court ruling, or other resolution of listed patent barriers.
Does Diclegis have biosimilar competition?
No. Diclegis is a small-molecule drug. Its relevant competitors are generic products approved through the ANDA pathway.
References
- U.S. Food and Drug Administration. (2023). Diclegis prescribing information.
- American College of Obstetricians and Gynecologists. (2018). Practice bulletin no. 189: Nausea and vomiting of pregnancy. Obstetrics & Gynecology, 131(1), e15-e30.
- U.S. Food and Drug Administration. (2013). FDA approves Diclegis for nausea and vomiting of pregnancy.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). Bonjesta prescribing information.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. §355(j).
